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Background: Medication review has been advocated to address the challenge of polypharmacy 
in older patients, yet there is no consensus on how best to evaluate its efficacy. Heterogeneity 
of outcomes reported in clinical trials can hinder the comparison of clinical trial findings in 
systematic reviews. Moreover, the outcomes that matter most to older patients might be under-
reported or disregarded altogether. A core outcome set can address this issue as it defines a 
minimum set of outcomes that should be reported in all clinical trials in any particular field 
of research. As part of the European Commission-funded project, called OPtimising thERapy 
to prevent Avoidable hospital admissions in the Multimorbid elderly, this paper describes the 
methods used to develop a core outcome set for clinical trials of medication review in older 
patients with multimorbidity.
Methods/design: The study was designed in several steps. First, a systematic review established 
which outcomes were measured in published and ongoing clinical trials of medication review in 
older patients. Second, we undertook semistructured interviews with older patients and carers 
aimed at identifying additional relevant outcomes. Then, a multilanguage European Delphi 
survey adapted to older patients was designed. The international Delphi survey was conducted 
with older patients, health care professionals, researchers, and clinical experts in geriatric phar-
macotherapy to validate outcomes to be included in the core outcome set. Consensus meetings 
were conducted to validate the results.
Discussion: We present the method for developing a core outcome set for medication review 
in older patients with multimorbidity. This study protocol could be used as a basis to develop 
core outcome sets in other fields of geriatric research.
Keywords: core outcome set, study protocol, polypharmacy, multimorbidity
Introduction
Patients aged 65 years and older are often exposed to polypharmacy in the context 
of multimorbidity.1,2 This increases the risk of adverse drug reactions and the cost of 
medications.3–6 Structured medication review has been shown to be an efficient way 
to optimize the quality of prescriptions in older patients.7,8 Medication review has 
recently been defined by the guidelines of the National Institute for Health and Care 
Excellence as “a structured, critical examination of patient’s medications with the 
objective of reaching an agreement with the patient about treatment, optimising the 
impact of medications, minimising the number of medication-related problems and 
reducing waste”.9 A wide range of randomized controlled trials (RCTs) have been 
performed to evaluate the impact of medication review on clinical, patient-reported, 
and economic outcomes. Several systematic reviews and meta-analyses have, therefore, 
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been conducted to summarize the effectiveness of medication 
review in various clinical settings.7,8,10–20 However, the het-
erogeneity of outcomes reported in the RCTs has limited the 
quality of the conclusions. Robust meta-analyses could be 
performed for only a few outcomes, including hospitalization 
and death.15–17,21 For other outcomes, results were essentially 
summarized in a descriptive way because of heterogeneity in 
the choice and definition of the outcome measures.17–20,22
Outcome reporting bias is an under-recognized problem 
that affects the conclusions in a substantial proportion of 
systematic reviews and meta-analyses.23–25 Moreover, out-
comes that are considered highly relevant to older adults 
are often ignored in RCTs.26,27 The development of a core 
outcome set (COS) can address the challenge of obtaining 
a consensus on which outcomes are deemed essential for 
all stakeholders involved in the management of a given 
condition, including patients. A COS is an agreed stan-
dardized collection of outcome variables that should be 
measured and reported in all trials for a specific condition 
or clinical area.28 It has the potential to reduce heterogeneity 
between trials, lead to research that is more likely to mea-
sure relevant outcomes, and enhance the value of evidence 
synthesis by reducing the risk of outcome reporting bias.29 
COS has been developed in various fields of medicine, such 
as nonspecific low back pain, breast cancer surgery, and 
acute diarrhoea.30–32 Currently no COS has been developed 
specifically for clinical trials of medication review in older 
patients with multimorbidity.
The European Commission-funded OPERAM (OPtimis-
ing thERapy to prevent Avoidable hospital admissions in the 
Multimorbid elderly) project will perform a multicenter RCT 
to assess the impact of an intervention to optimize pharma-
cotherapy and to enhance compliance in 2,000 multimorbid 
older patients. To tackle the challenge of measuring relevant 
outcomes for these patients, the development of a COS for 
clinical trials of medication review in older patients with 
multimorbidity was planned. The results of the COS will be 
implemented into the RCT.
The aim of this study protocol was to describe a method 
that could be used to develop a COS for future use in trials 
of older patients with multimorbidity. The specific scope 
of our COS was “Medication review among patients aged 
65 years and older with polypharmacy ($5 medications) and 
multimorbidity ($2 chronic conditions/diseases)”.
Preliminary search
Before starting the development of a COS on medication 
review in older patients with multimorbidity, we checked 
that there was no existing or ongoing work on this subject. 
A systematic search was performed in the COMET (Core 
Outcome Measures in Effectiveness Trials) database 
which collects all details of ongoing and completed COS 
developments.33 We found one ongoing study of COS 
development on prescribing in older patients living in the 
nursing home setting. The primary investigator of this COS 
study was contacted, and after a discussion, the conclusion 
was that the two studies would be complementary with a 
slight overlap. Furthermore, an ongoing project attempting 
to develop a COS for the assessment and management of 
frail older patients was retrieved.34 The principal inves-
tigator was contacted for discussion and the reply was 
that the COS study had not yet started.
Overview of the work performed
The development of the COS was achieved through a 
four-step approach represented in Figure 1. The scope was 
defined by the OPERAM research team in order to best fit 
with the OPERAM project and to be of the highest relevance 
for future RCTs in this research topic. We followed the 
guidelines published for the development of a COS35,36 and 
the project was registered on the COMET database (http://
www.comet-initiative.org/studies/details/806?result=true). 
The methodological aspects addressed in this study protocol 
are detailed in Table S1, following recommendations made 
by Sinha et al.37 A steering committee was set up with the 
members of the OPERAM board and the local principal 
investigators of the participating centers.
Step 1: systematic review
Purpose
The objective of this systematic review was to identify all 
outcomes used or planned to be used in previous and ongoing 
studies of medication review in older patients. Owing to time 
and resource constraints, we performed an update of a recent 
systematic review on medication review published in 2014 by 
Lehnbom et al,10 combined with a systematic search in random-
ized clinical trial registries and in the Cochrane Database.
Study selection
We considered RCT, quasi-RCT, and other prospective inter-
ventional studies that investigated the effect of medication 
review performed in patients aged 65 years or older.38 The 
following studies were excluded: studies published before 
2000; studies predominantly including patients younger 
than 65 years old; retrospective studies; medication reviews 
for a specific disease or condition (eg, chronic heart failure) 
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or as part of a multifaceted approach, namely a complex 
intervention that contained interventions in addition to 
medication review (eg, physiotherapy, nutritional advice, 
and occupational therapy); no outcome reported; or a sample 
size that was lower than 50 participants.
Search strategy
We used the studies identified in a recent systematic review 
on medication review published in 2014 by Lehnbom et al,10 
the aim of which was to examine the evidence regarding 
the effectiveness of medication review to improve clinical 
outcomes in hospitals, in the community, and in aged care 
facilities. Lehnbom et al identified 43 studies published 
before March 2014 that investigated the effectiveness of 
medication review.10 As the purpose of the present systematic 
review was different in nature, we used only the result of 
the search strategy, that is, the list of the published studies 
included in the systematic review. The queries developed by 
Lehnbom et al were used to identify all eligible studies pub-
lished during the period between March 2014 and July 2015. 
Two reviewers (LP and J-BB) independently assessed the 
title, abstracts, and full texts of studies resulting from the 
searches. A third reviewer (AS) was called upon to resolve 
any divided opinion toward consensus, if needed.
In addition, we used the search terms from the system-
atic review to identify RCT protocols related to medication 
review on the following RCT websites: the World Health 
Organization (WHO) international clinical trials registry 
platform,39 the EU Clinical Trials Register,40 and the US 
Clinical Trials Register.41 BB and J-BB first assessed the 
titles and subsequently the summaries of the RCTs protocols 
identified by the queries. AS was called upon to resolve any 
divided opinion toward consensus, if needed. It was verified 
if protocols had matured to full report publications. If this 
was the case, the publication was evaluated as mentioned 
above and added to the set of published studies.
Finally, the search terms from the systematic review 
were also used to identify relevant Cochrane reviews. JBB 
identified the relevant Cochrane systematic reviews and 
then extracted the eligible original studies in the selected 
Cochrane systematic reviews. The selection process was 
checked by AS.
Figure 1 representation of the four-step approach used to develop the core outcome set.
Abbreviation: CoS, core outcome set.
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data extraction
All data extractions on outcomes and outcome measurement 
instruments were performed by two independent reviewers 
(ST and J-BB for RCT protocols; LP and J-BB for published 
studies). Any disagreement was resolved by discussion and 
consensus. AS was called upon to resolve any divided opinion 
toward consensus, if needed. The characteristics of the RCT 
protocols and the published studies were extracted by JBB 
and included the following: setting (hospital setting, primary 
care, and nursing home); number of patients intended to be 
recruited (RCT protocols) or actually included (published 
studies); and mean age (published studies only).
Outcomes used to compare the two groups under inves-
tigation (in RCTs and prospective before/after studies) or 
to evaluate the medication review process were extracted: 
name of the outcome in free text (what was measured in 
published studies and what was planned to be measured in 
protocols); primary or secondary outcome. For each out-
come, the following data about measurement instrument 
were extracted from published studies: which instrument was 
used to measure the outcome (free text); was the method of 
measurement clearly defined? (the reviewer answered “Yes” 
if he/she believed that another researcher could reproduce 
the procedure and its measurement with the explanations 
provided in the “Methods” section). As the data provided 
in RCT protocols are often less detailed than in published 
studies, the data on measurement instruments were extracted 
when available.
Classification of outcomes into health 
domains and subdomains
The classification of the outcomes extracted from the 
included studies was achieved in several steps, starting 
from identifying a first list of subdomains and matching 
outcomes to subdomains. The list was then refined by the 
research team and additional experts. The objective was 
to obtain a consensus on subdomain terms, to avoid major 
overlaps between subdomains, and to aggregate subdomains 
into health domains. The OMERACT filter 2.0 was used to 
organize this classification. A total of 57 subdomains were 
identified and grouped into 8 health domains.
Step 2: qualitative study
Purpose
In the development of a COS, it is recommended to conduct 
a qualitative study before the Delphi survey to identify 
unknown and relevant outcomes that the population of inter-
est notice and care about.36
Participants
The qualitative study was conducted in two Belgian teaching 
hospitals (the Cliniques Universitaires Saint-Luc, Université 
catholique de Louvain [UCL], Brussels, located in an urban 
area and the CHU UCL Namur Godinne, located in a rural area 
of Belgium). The study was approved by the local research 
ethics committee (“Comité d’Ethique hospitalo-facultaire des 
Cliniques universitaires Saint-Luc”). Patients and caregivers 
were included after a consent form was signed. Eligible 
patients were patients aged 65 and older, taking at least five 
daily prescription medications at home and hospitalized in 
specialist departments of Geriatric Medicine, Internal Medi-
cine or Orthopaedic Surgery. The exclusion criteria were: 
patient’s refusal to participate and inability to give informed 
consent (eg, dementia). Eligible caregivers were carers pro-
viding assistance to patients aged 65 years or older taking at 
least five daily prescription medications at home. The only 
exclusion criterion here was the refusal of the caregiver.
Interviews
With the agreement of the physician in charge of the patient’s 
care, a pharmacist researcher (AS or OD) informed the 
patient or the caregiver about the study and its objectives. 
Participants provided informed consent prior to the one-to-
one interview. A semistructured approach was used. The 
interviews took the form of a discussion about the patient’s 
medications, the concept of medication review, the percep-
tion of the patient of risks and benefits of his/her medication, 
and what he/she would expect from a medication review. 
A topic guide was developed, pilot-tested, and used by both 
investigators (AS and OD). Interviews were recorded and 
then transcribed verbatim.
Audio recordings of the semistructured interviews were 
analyzed using NVivo10® software. The analysis was con-
ducted by two independent researchers (a physician and a 
psychologist) using an interpretative approach. Key issues 
were identified in the transcripts and then classified under 
more global themes. The analysis focused on generating 
a comprehensive list of outcomes that are important to 
older patients.
Step 3: preparation of a Delphi 
survey adapted to older patients
Purpose
The purpose of the Delphi survey is to gather opinion and 
to reduce the number of outcomes to a priority list for 
consideration in future clinical trials on medication review 
in older patients with multimorbidity. Some important 
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methodological aspects have to be defined before starting 
the Delphi survey to improve both the quality of the survey 
and its reporting, as detailed in Table S1.37
list of eligible outcomes to propose
The results from the systematic review and the qualitative 
research were merged into a unique list of outcomes through 
a consultation exercise with clinical experts and researchers. 
The selected outcomes were then classified into outcome 
domains and areas according to the OMERACT (Outcomes 
Measures in Rheumatology) classification.35 Definition from 
the OMERACT Filter 2.0 is given in supplementary data 
(Supplementary material).
The selected outcomes were then written in four lan-
guages (Dutch, English, French, and German) in medical 
terms and in plain language with an explanation if needed. 
The plain language terms and explanations were tested 
for understanding with older patients and improved with 
their suggestions. This procedure provided a final list of 
outcomes understandable to all Delphi participants, espe-
cially the patient group. This list of outcomes and the results 
of the systematic review and the qualitative study were 
not provided to participants before the first round of the 
Delphi survey.
Key stakeholders to recruit
There is currently no consensus regarding the appropriate 
sample size of a Delphi survey. In recent studies using a 
Delphi survey methodology to develop a COS, the number 
of participants varied widely from 13 to 222.37 The ratio 
between patients and health care providers is also unclear, 
but the patients should be sufficiently represented. On the 
basis of current recommendations and on discussions among 
research team members, we agreed on the following list of 
stakeholders to recruit:
1. Group 1 (35%): patients and family caregivers; patients 
aged 80 years and over should represent a significant part 
of this group.
2. Group 2 (35%): health care professionals including gen-
eral practitioners (GPs), community and hospital pharma-
cists, geriatricians, specialists in internal medicine, and 
nurses. We defined that GPs should be the majority in this 
group (30%–40%), given their central role in medication 
review.
3. Group 3 (30%): researchers from the field of medication 
review and from other areas (eg, sociologists of ageing), 
representatives of scientific organizations, and policy 
makers.
A higher attrition rate was anticipated for the patients and 
GPs. The characteristics and the number of each category of 
participants to be recruited in each center were determined 
in order to ensure a balanced representation of the four 
countries involved.
Participants from groups 1 and 2 were all recruited 
locally by the primary investigator of each participating 
center (Berne, Brussels, Cork, and Utrecht). Researchers 
from nonmedical fields, representatives of scientific orga-
nizations, or policy makers were also recruited locally. 
Researchers from the field of medication review were 
recruited on the basis of their publication profile. A search 
performed in Scopus® identified researchers with a high 
number of publications since 2000 on the subject of 
medication review and inappropriate prescribing in older 
patients. The details of the composition of each group of 
stakeholders and the number of participants are presented 
in Table 1.
The physicians, pharmacists, nurses, or researchers 
directly involved in the OPERAM project were not allowed 
to participate to the Delphi survey because of the potential 
conflict of interest.
Methods for the delphi survey
online questionnaires and anonymity
The Delphi survey was developed by a company (WorldAPP®) 
that specializes in online surveys in order to ensure anonymity 
of the answers, to allow personal anonymized feedback at 
Rounds 2 and 3, and to develop a flexible online solution 
adapted to both very old patients and highly graduated partici-
pants. The complete online solution proposed the following: 
1) an online questionnaire for health care professionals and 
experts that included medical terms, plain language terms, 
and their explanations; 2) an online questionnaire for patients 
and carers that did not show the medical terms in order to 
avoid confusion; 3) multilanguage interface; 4) a short video 
that explained the concept of medication review and the aim 
of the study (one for patients, one for other stakeholders, 
both in four languages); and 5) a possibility to propose new 
outcomes or to make comments on the outcomes proposed. 
The online survey can be viewed and tested (version sent 
for Round 1) through the following website: http://app.
keysurvey.fr/f/1038815/5ded/. In this online test version, the 
user must choose the language, the participant category, and 
the age group before getting the questionnaire. During the 
Delphi survey, these questions were prefilled and hidden, so 
the participants had direct access to the questionnaire in the 
right form and in adequate language.
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A printable version of the online questionnaire was 
proposed for each round to older patients who did not want to 
fill the questionnaire online. It was also made possible to fill 
the questionnaire by an interviewer who helped older patients 
during the Delphi survey (see the section on “Maximizing 
response rate”).
WorldAPP ensured anonymity of the answers. The results 
database was sent in an anonymous form to UCL (coordinating 
research center) for analysis. The participants did not know 
the identity or the answers of any of the other participants.
Consensus
In each round of the Delphi survey, participants were asked to 
score each of the outcomes listed using the GRADE process, 
which suggests a scale of 1–9 to rank their importance.42 
Ratings from 7 to 9 indicate outcomes of critical importance, 
ratings from 4 to 6 indicate outcomes that are important but 
not critical, and ratings from 1 to 3 indicate outcomes of 
limited importance.
The definition of consensus during the Delphi survey 
was similar to the definition used in previous COS studies 
or in study protocols.43 We considered that a consensus 
would be reached to include a given outcome in the COS 
(“consensus-in” rule) if most of the participants (75% or 
more) considered the outcome as critically important (ratings 
of 7–9) and very few participants (15% or less) considered 
it of limited importance (ratings of 1–3).
Step 4: running the Delphi survey
This Delphi survey was performed in four centers from four 
European countries: UCL, coordinating centre (Belgium), 
University of Bern (Switzerland), University College 
Cork (Ireland), and University Medical Centre Utrecht 
(Netherlands). Ethical approval was sought locally in 
each center and obtained for the project in Belgium 
(“Comité d’Ethique hospitalo-facultaire des Cliniques 
universitaires Saint-Luc”) and Ireland (“Clinical Research 
Ethics Committee Of The Cork Teaching Hospitals”). 
Participants signed a consent form to take part in the study 
in these two centers. In the Netherlands (“Medical Ethics 
Review Committee UMC Utrecht”) and Switzerland 
(“Kantonale Ethikkommission Bern [KEK]”), official 
ethical approval was not required as the research ethics 
committees confirmed that the Medical Research Involving 
Human Subjects Act was not applicable. Completion of the 
questionnaire deemed consent in these two centers.
Maximizing response rate
The health care professionals and experts received an email 
containing a personal link to the questionnaire. The email 
containing the personalized link to the survey for patients 
and carers was sent to the local principal investigator. It 
was expected that this survey would be difficult to answer 
for older patients. All patients were proposed to answer the 
questionnaire with the help of a local interviewer at their own 
Table 1 repartition of all stakeholder groups and subgroups with number planned to be recruited in each center
Participant groups Characteristics Place of recruitment
Locally in each center* International
Group 1: patients and carers 16
Patients 65–80 years old and living at home 6
.80 years old and living at home 6
Carers living at home 2
Patient/carer Nursing home 2
Group 2: health care professionals 13
Primary care GP 6
Pharmacists 1
Nurses (1 at home; 1 in nursing home) 2
Secondary care Physicians 2
Clinical pharmacists 1
Nurses 1
Group 3: scientifics and experts 5 20
researchers specialized in medication review 20
Researchers in related fields (nonmedical) 2
Policy makers 2
Experts from professional associations 1
total number to be recruited 136 20
Notes: *Four centers in total: university of Bern, Switzerland; university College Cork, Ireland; université catholique de louvain, Belgium; university Medical Centre 
utrecht, Netherlands.
Abbreviation: GP, general practitioner.
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home or during a consultation. When this was not necessary, 
the principal investigator forwarded the email to autonomous 
patients and carers. The questionnaire remained online for 
3 weeks and automated reminder emails were sent every 
7 days after the initial invitation. The list of the participants 
who had answered the questionnaire during a given round 
was sent to the local principal investigator of each center. He/
she sent a personalized reminder to nonresponders after each 
automated reminder and before the end of each round.
rounds 1–3
Round 1: Participants were asked to rate each outcome as 
described under Consensus section. Participants could pro-
pose to add additional outcomes and to comment on their 
ranking. Answers to the questionnaire were analyzed glob-
ally and by the stakeholder group. Any additional outcome 
identified by participants was checked by two researchers 
and discussed with the steering committee.
Round 2: Participants who did not participate in Round 1 
were not invited for Round 2. Outcomes considered as “very 
important” (rating 7–9) by 75% or more participants in at 
least one stakeholder group were further presented in Round 2 
with additional outcomes suggested by the participants, if 
relevant. In Round 2, the participants were presented with 
their own results and the results of each stakeholder group in 
Round 1. They were asked to rerate the importance of each 
of the outcomes.
Round 3: Participants who did not participate in Round 2 
were not invited for Round 3. Outcomes considered as “critical” 
(rating 7–9) by 75% or more participants in at least one 
stakeholder group were further presented in Round 3. All 
participants were asked whether the outcomes should be 
systematically measured in all studies on medication review 
in the elderly (answer YES or NO). Participants were 
specifically encouraged not to rate YES for all presented 
outcomes.
Consensus meetings
Adaptations in the methods used to obtain consensus were 
required. The two main changes concerned the removal of 
outcomes that did not meet the consensus-in rule in any 
group (ie, the consensus-out rule was extended) and the 
change of the question in Round 3 (answer YES or NO 
instead of Likert scale). These changes were discussed 
and validated with the steering committee, the OPERAM 
research team, and two external experts in COS develop-
ment. They were also discussed with participants during 
consensus meetings.
A face-to-face consensus meeting with all groups of 
stakeholders who participated in the Delphi survey was not 
feasible due to the number of participants, the age of the 
included patients, their diverse locations across Europe, the 
time constraint, and the various languages involved. We, 
therefore, proposed to perform adapted consensus meetings 
after each round.
After Rounds 1 and 2, two consensus meetings were 
performed by teleconference: the first one with health care 
professionals from UCL who participated in the Delphi 
survey and the second one with the steering committee. 
Patients and carers were not invited because of the difficulty 
of performing a long teleconference (over 1 hour) for old and 
very old patients. However, local investigators from each 
center had participated in interviews with old and/or very 
old participants and could provide an indirect feedback from 
these participants. Researchers specialized in medication 
review were not invited because of time constraint and high 
workload of these participants. However, they frequently 
made very clear comments on the online questionnaire that 
could be included during these consensus meetings.
After Round 3, three consensus meetings were held. The 
results of each round of the Delphi survey were presented 
at the meeting, with the consensus results from Round 3 
analyses used as the starting point for discussion. The goal 
was to comprehensively address points for discussion and 
to validate the final COS. The first consensus meeting was 
a face-to-face one with patients and carers from UCL and 
was conducted in a location close to the homes of several 
participants. The second consensus meeting was a teleconfer-
ence with health care professionals from UCL. The third was 
a teleconference with researchers specialized in medication 
review and the steering committee. The interaction between 
the participants of the three groups was thus indirect, with 
the feedback and opinions of each group being transmitted 
to the other group by the two coordinators of this study 
(J-BB and AS).
Discussion
Both the European Union Geriatric Medicine Society and 
the American Geriatrics Society have identified that defining 
outcomes that are relevant for older people are important 
for overcoming the recognized age discrimination in clini-
cal trials.27 COS can contribute to meet this challenge. It 
is, therefore, important that clinicians and researchers in 
geriatric care are well-equipped to develop COS. This study 
protocol presents the methodology to develop a COS for 
trials of medication review in patients aged 65 years and 
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older with multimorbidity. We demonstrated a feasible 
way to involve very old patients and other stakeholders in 
the process of selecting the most relevant outcomes for use 
in future trials. We have contributed significantly to the 
development of the European OPERAM RCT and future 
RCTs of medication review by improving the quality of 
outcome reporting.
Strengths and limitations
The strengths of this study include: 1) methods following 
the guidance of initiatives like COMET and OMERACT; 
2) the involvement of a large number of older and very 
old patients; 3) the involvement of a large expert panel of 
stakeholders representing various disciplines and countries; 
and 4) multi-institutional contributions. Some limitations 
should be mentioned. The applicability of the process 
described in this manuscript may be limited because it 
included very old patients and required interviews of older 
patients – a process that is less standardized than question-
naire completion.
A COS will have an impact only if it is consistently 
implemented in most trials of relevance in any given area of 
research. Trialists, regulators, and those who fund and publish 
clinical trials should engage to ensure that the COS is used. 
Having a strong outcome data would then help clarify if and 
how medication review can be effective, in which popula-
tion can it be useful, and which are the important contextual 
factors that support positive outcomes.
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Table S1 Methodological aspects to be defined before starting the Delphi survey to improve both the quality of the survey and its 
reporting, as recommended by Sinha et al2 along with the paragraph of the study protocol that addressed each given issue
Size and composition of the panel
The total number of participants invited, and the number who completed the first round table 1
Whether the following types of participants were involved in the study: clinicians (and whether 
they were eligible on the basis of treating patients with the condition of interest, or whether 
clinical trial involvement was an additional requirement), patients or their families, researchers, 
biostatisticians, representatives from the pharmaceutical industry, representatives from drug 
regulatory authorities, or other types of participants
table 1 and Key stakeholders to recruit section
the proportion of each type of participant described above table 1
How participants were identified/sampled Key stakeholders to recruit section
Methodology of the Delphi process
Administration of questionnaires: postal, email, internet, in person (eg, at a clinic), or at a meeting Maximizing response rate section
Information about outcomes, known to the facilitators before the study, which was provided 
to participants before the first round: for example, if the Delphi process followed a review of 
outcomes measured in clinical trials, were the results of the review shared with participants? 
Alternatively, if some work had been conducted prior to the delphi survey (eg, workshop 
meeting, or focus groups among patients), were the results presented to the participants?
list of eligible outcomes to propose section
How outcomes were considered in the first questionnaire: were participants asked an open 
question, that is, no outcomes were initially listed, or were they asked to comment on a 
prespecified list? If the latter, was the source of the list identified? Where possible, the questions 
asked to participants should be described in the methods, or made available to the reader, as 
supplementary information
list of eligible outcomes to propose section
online questionnaire and anonymity section
rounds 1–3 section
What was asked in subsequent rounds: where possible, the questions asked to participants should 
be described in the methods, or made available to the reader, as supplementary information
rounds 1–3 section
Feedback to participants after each round: if the results were not fed back, but only certain 
outcomes were carried forward to the next round (eg, only those suggested by at least 10% were 
carried forward), this should be clearly described
rounds 1–3 section
level of anonymity should be described: In order to be “fully anonymised”, participants should 
not know the identities of the other individuals in the group, nor should they know the specific 
answers that any other individual gave. In studies that are “quasi-anonymised”, the participants 
should know the identities of some or all of the other individuals, but should not know how they 
individually responded to any of the questions in any round. In studies that are not anonymized, 
participants must know the identity of some or all of the other individuals, and also know how 
some or all of them responded to any of the questions in any round
online questionnaires and anonymity section
If a predetermined definition of consensus was used, this should be clearly described in the 
methods section of the study report
Consensus section
Were nonresponders invited to subsequent rounds, or were they excluded from the rest of the 
study? Were additional people invited as the delphi survey progressed?
rounds 1–3 section
Supplementary materials
Definitions from OMERACT filter 2.01
Core area: An aspect of health or a health condition that 
needs to be measured to appropriately assess the effects of a 
health intervention. Core Areas are broad concepts consisting 
of a number of more specific concepts called Domains.
(Sub) Domain: Component of Core Area: a concept to be 
measured, a further specification of an aspect of health, 
categorized within a Core Area.
Outcome: Any identified result in a (Sub) Domain arising 
from exposure to a causal factor or a health intervention 
(Adapted from John Last, Dictionary of Epidemiology. 
Toronto: Oxford Press 1995).
Measurement instrument: A tool to measure a quality or 
quantity of a variable, in this context a (Sub) Domain or a con-
textual factor. The tool can be a single question, a questionnaire, 
a score obtained through physical examination, a labora-
tory measurement, a score obtained through the observation 
of an image, and so on.
Core Outcome set or Core Domain set: For studies of health 
interventions, the minimum set of Domains and Subdomains 
necessary to adequately cover all Core Areas, that is, ade-
quately measure all relevant concepts of a specific health con-
dition within a specified setting. Describes what to measure. 
Currently, the COMET initiative uses the term “Core Outcome 
Set” for this concept.
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